We have previously found evidence of contaminants in 0.9% saline packaged in polyvinyl chloride (PVC) for clinical use. For this current study we asked two questions:
Saline solutions are used in the care of most hospital inpatients worldwide. We have previously investigated 0.9% saline packaged in compounded polyvinyl chloride (PVC) bags for intravenous use 1 . From pH studies we concluded that contaminants might have been leaching from the PVC into the solutions. For this current study we asked two questions: (1) what are the organic chemical contaminants in solutions packaged in PVC? and (2) do the contaminants vary in bags manufactured in different countries?
METHODS
Pairs of commercial bags of 0.9% saline for human intravenous use were obtained from hospital stores in Australasia (100 ml, Baxter Healthcare, Toongabbie, N.S.W., Australia), Europe (500 ml, SIFRA, Isola della Scala, VR, Italy), and North America (100 ml, Baxter Healthcare, Deerfield, IL, U.S.A.). Pairs were used as duplicates for analysis.
All chemical analyses were performed at the Royal Melbourne Institute of Technology (RMIT) University in the School of Applied Science. Research Ethics Committee approval was not needed for this in vitro study because human and animal subjects were not involved. All glassware was subjected to a multistage cleaning protocol to prevent cross-contamination. All reagents were screened for trace levels of phthalates and semi-volatile organic compounds. High purity standards (Sigma-Aldrich, Castle Hill, New South Wales, Australia) were used to prepare di-2-ethylhexyl phthalate, di-n-butyl phthalate, 2-ethyl hexanol, phthalic acid, cyclohexanone, 4-nonyl phenol, 4-toctyl phenol, and butylated hydroxytoluene.
Saline from the three sets of PVC bags was quanti-tatively analysed using high-resolution capillary gas chromatography-mass spectrometry 2 . The instrumental system consisted of a gas chromatograph (6980 Plus, Agilent, Palo Alto, CA, U.S.A.), directly coupled to a mass selective detector (5973, Agilent, Palo Alto, CA, U.S.A.). Method blanks were carried out prior to any sample extraction to ensure that the extraction method and regents were free from contamination. Australasian and European PVC bags were analyzed to determine the contaminant sources. Segments of the bags with and without printing, and the joints at the bases of the bags were subjected to qualitative analysis using thermodesorption under helium to a temperature of 120°C. Gas chromatography-mass spectrometry followed 3 .
RESULTS
Twenty-four different contaminants were detected among the three sample groups: Australasian, European, and North American ( Table 1) . Several differences between the sample groups in the contaminants were noted. Cyclohexanone was found in the Australasian and North American solutions in concentrations of around 1000 µg/l. Cyclohexanone was not detected in the European solutions. Thermodesorption ( Table 2 ) analysis suggested that the joints at the bases of the bags were the source of the cyclohexanone.
Both the Australasian and European solutions were found to be contaminated with t-butyl cyclohexanol in concentrations greater than 500 µg/l and t-butyl cyclohexanone in concentrations greater than 50 µg/l. These chemicals were not found in the North American solutions.
Data from thermodesorption of PVC bags ( Table  2) suggest that printing ink on the bags was the source of t-butyl cyclohexanol and t-butyl cyclohexanone. Cyclohexanone was detected in segments from the joints at the bag bases. Phthalic anhydride is a breakdown product of DEHP that occurs throughout the bags and is common to all segments. Acetic anhydride and ethyl hexanol are thermal breakdown products of DEHP that arise from heating to 120°C during analysis.
DISCUSSION
Using bags from Australasia, Europe and North America, we found twenty-four different organic contaminants in PVC packaged saline solutions for human intravenous use. Many have not been reported before. The types and relative concentrations of contaminants differed between the samples from different countries. The Australasian and North American bags, although manufactured in different countries, were originally supplied by subsidiaries of the same parent company. Another company manufactured the European bags. Analysis of the PVC bags suggested several sources of the leached contaminants: the PVC plastic itself, joints in the PVC bag base, and printing ink on the outside of the bags. Although we used a small number of samples, this approach is common in the chemical analysis of complex mixtures [3] [4] [5] . Prior to each analysis, blank runs were performed showing no contamination. This confirmed that the chemicals found in the analyses were contaminants of the solutions and did not originate from the analytical equipment. Because of the small numbers, however, these results cannot be extrapolated to all products from each manufacturer.
PVC is manufactured as a hard plastic used in applications such as pipes for domestic plumbing. To provide the softness or plasticity needed for many medical applications, plasticizers are added 6 . The most commonly used plasticizer is diethylhexyl phthalate (DEHP) 6 . For bags for intravenous fluids other materials are used to make plugs and ink for the bags 6 . Some of the observed differences in contaminants detected in our study can be explained by different manufacturing, printing and storage methods 6 . This also partly explains differences between our results and previous findings 3, 5 . We found previously unreported contaminants, particularly t-butyl cyclohexanone and t-butyl cyclohexanol, but failed to find some contaminants found by Arbin and colleagues 5 and Wahl and colleagues 3 .
We regarded contaminants as important if they had known biological activity or were present in higher concentrations. The important contaminants differed between the groups of samples, but included diethylhexyl phthalate (DEHP), 2-ethyl hexanol, cyclohexanone, t-butyl cyclohexanone, and t-butyl cyclohexanol. The importance of these contaminants to human morbidity is unclear. PVC products with the plasticizer DEHP have received attention in scientific and lay publications because of toxic biological activity of DEHP, or its breakdown products, reported in animal organ systems: liver, lung heart, kidneys, and reproductive tract; as well as adverse foetal effects [7] [8] [9] . After extensive reviews, the European Commission 10 , the United States' Centers for Disease Control and Prevention 11 , and Food and Drug Administration (FDA) 12 , and Health Canada 13 have expressed concern about possible DEHP toxicity in humans. In the past, DEHP research has focused on liver carcinogenicity in rats, however, human carcinogenicity now seems unlikely 7, 9, 10 . Human data for other effects of DEHP are very limited 9,10 , but two recent human studies have found associations between plasma DEHP levels and reduced gestational age 14 and endometriosis 15 .
After an exhaustive review, the FDA concluded that the tolerable daily parenteral intake for DEHP is 0.6 mg/kg/day. The report estimates that maintenance fluid therapy of about 30 ml/kg/day of crystalloid packaged in PVC, without additives, would infuse about 1% of the tolerable intake in adults and about 5% in neonates. Addition of lipophilic drugs can greatly increase the daily does of DEHP from PVC infusion sets. Midazolam led to a 50% increase, fentanyl a fivefold increase and propofol a 600-fold increase 12, 16 . The FDA report 12 notes that when used in isolation as maintenance fluids, without added lipophilic drugs, PVC packaged fluids probably present little risk to patients. The report notes, however, that critically ill patients will often receive high daily doses of DEHP from several sources including from PVC intravenous fluids bags.
Compared with DEHP, little is known about cyclohexanone toxicity. Carcinogenicity data are limited, but liver and renal toxicity were found in dogs 17 .
Nothing is known about biological interactions of DEHP and cyclohexanone. There is no readily available toxicological information on t-butyl cyclohexanol or t-butyl cyclohexanone. We also found important concentrations of 2-ethyl hexanol, a breakdown product of DEHP. Pollack and colleagues 18 found that 2-ethyl hexanol enhances some of the liver enzyme effects of DEHP in rats. This finding suggests the possibility of other biological interactions due to combinations of contaminants 8 .
Every day, saline solutions are administered to hundreds of thousands of patients. As manufacturers point out, there is no recorded case of an acute adverse event associated with intravenous fluids due to the PVC packaging 19 . Most doctors, however, are unaware of contaminants from PVC packaging or several international governmental reports on the topic 10, 12, 13 . Our study demonstrates that contaminants may vary even within one company, probably due to regional differences in materials such as ink. Based mainly on DEHP research, the European Commission recently concluded that possible risks associated with PVC medical devices including intravenous fluid bags are outweighed by the known advantages 10 . However, the Commission has strongly suggested that detailed studies be conducted 10 . The FDA recently reached similar conclusions, but focused on DEHP alone 12 . Large doses of DEHP, often exceeding the tolerable daily intake, are infused with blood products and during procedures such as extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass and haemodialysis 12 . Alternatives to PVC packaging are now available in some countries 20 with ongoing research 19, 20 . Health Canada has made several recommendations 13 (Figure 1) including that lipophilic drugs should not be administered in PVC packaged fluids to at-risk patients, particularly prepubertal boys. This recommendation is relevant for anaesthetists and critical care physicians.
Further research is needed to examine the toxicology of individual contaminants as well as combinations of the contaminants 8, 13 . Industry commentators 21 have suggested that pressure on manufacturers and hospitals from activists 22 may hasten the introduction of alternative packaging for intravenous fluids. As new packaging is introduced, clinical trials should examine the biological activity and possible toxicity of the new products compared to PVC packaged intravenous fluids. Further, many of the minor contaminants we found are likely to be products from reactions during manufacture from a small number of major contaminants. We are conducting a separate investigation of the origins and formation of these compounds.
DEHP containing devices should not be used in the following circumstances:
•In all newborns and in prepubertal males, for high exposure procedures such as ECMO (except when heparin coated to prevent leaching), during cardiac surgery, during total parenteral nutrition, and double volume exchange transfusions; •In some adults such as heart transplant patients, those undergoing cardiac bypass, hemodialysis patients, and pregnant and lactating women;
•When administering lipophilic drug formulations;
•In adult trauma patients who fall into a potentially sensitive population (heart transplant recipients, pregnant and lactating women). 
